Webinar
ELRIG Drug Discovery 2026: Advancing AI Drug Discovery with Endogenous Protein Tagging
Presented by EditCo, Promega, and Recursion · October 14, 2026
Watch the on-demand session.
How can researchers accelerate AI-driven drug discovery and validate novel therapeutic targets in a biologically relevant context?
In this scientific workshop, experts from EditCo, Promega, and Recursion explore how endogenous protein tagging and scalable CRISPR cell engineering enable more reliable target validation and drug screening.
Learn how Promega’s HiBiT technology and EditCo’s engineered cell models help researchers measure native protein levels, investigate targeted protein degradation, and generate functional data to advance novel oncology targets. Recursion shares how it integrates AI, automation, and phenotypic screening to identify and validate promising drug targets.
Discover how combining AI-driven discovery with biologically relevant cell models can help bridge the gap between computational predictions and experimental validation.